Evercore ISI lowered the firm’s price target on Cardlytics (CDLX) to $1 from $2 and keeps an In Line rating on the shares following the company’s Q4 report and Q1 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDLX:
- Cardlytics Warns of Major Risks if Bridg Platform Sale to PAR Technology Falls Through
- Cardlytics Earnings Call: Profitability Up, Revenue Under Strain
- Cardlytics price target lowered to $1.25 from $1.50 at Lake Street
- Cardlytics reports Q4 adjusted EPS 3c, consensus (7c)
- Cardlytics sees Q1 revenue $35M-$40M, consensus $48.7M